COMMUNIQUÉS West-GlobeNewswire
-
Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
23/07/2024 - 15:00 -
Novogene to Power Cancer, Rare Disease, and Environmental Research with PacBio Sequencing
23/07/2024 - 15:05 -
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
23/07/2024 - 15:15 -
Leviton Canada fait un don de 100 000 $ à la Fondation de l’Hôpital de Lachine pour améliorer les services et les soins dans l’Ouest-de-l’Île
23/07/2024 - 15:33 -
Leviton Canada donates $100,000 to the Lachine Hospital Foundation to expand services and care in the West Island
23/07/2024 - 15:33 -
Acentra Health Names Brett Barton as Senior Vice President of Client Experience
23/07/2024 - 15:44 -
Pro League Network teams up with Birches Health on Responsible Gaming & Problem Gambling initiatives
23/07/2024 - 17:14 -
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2024
23/07/2024 - 17:52 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 29 - 2024
23/07/2024 - 18:00 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
23/07/2024 - 18:00 -
NADP Revitalizes its Foundation
23/07/2024 - 18:01 -
Progyny, Inc. Announces Details for Its Second Quarter 2024 Results Report
23/07/2024 - 20:00 -
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/07/2024 - 22:01 -
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
23/07/2024 - 22:05 -
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
23/07/2024 - 22:05 -
The Ensign Group Schedules Second Quarter Earnings Call for Friday, July 26, 2024
23/07/2024 - 22:05 -
NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024
23/07/2024 - 22:05 -
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
23/07/2024 - 22:13 -
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
23/07/2024 - 22:15
Pages